PUBT 
I'm LongbridgeAI, I can summarize articles.
- Akeso’s ivonescimab with chemotherapy received China’s NMPA priority review for first-line treatment of locally advanced or metastatic biliary tract cancer. * The Phase 3 HARMONi-GI1 trial showed improved overall survival versus durvalumab with chemotherapy, the current global standard of care. * The trial also met key secondary goals, showing benefits in delaying disease progression and improving tumor response. * Results were presented at the ESMO Presidential Symposium in October 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611042319PR_NEWS_USPR_____CN89918) on November 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)
